A first-in-human study to investigate safety and tolerability of SAR446959 in participants with osteoarthritis of the knee

2024-514015-96-00 Protocol SAD18258 Human pharmacology (Phase I) - First administration to humans Ended

Start 20 Nov 2024 · End 18 Dec 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol SAD18258

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 230
Countries 1
Sites 1

Osteoarthritis

Key facts

Sponsor
Sanofi-Aventis Recherche & Developpement
Participant type
Patients
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Musculoskeletal Diseases [C05]
Trial duration
20 Nov 2024 → 18 Dec 2025
Decision date (initial)
2024-11-12
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-514015-96-00
WHO UTN
U1111-1306-6767

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Osteoarthritis

VersionLevelCodeTermSystem organ class
20.0 PT 10031161 Osteoarthritis 100000004859

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Sanofi-Aventis Recherche & Developpement

Sponsor organisation
Sanofi-Aventis Recherche & Developpement
Address
82 Avenue Raspail
City
Gentilly
Postcode
94250
Country
France

Scientific contact point

Organisation
Sanofi-Aventis Recherche & Developpement
Contact name
Clinical Sciences and Operations

Public contact point

Organisation
Sanofi-Aventis Recherche & Developpement
Contact name
Clinical Sciences and Operations

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ended 230 1
Rest of world 0

Investigational sites

Germany

1 site · Ended
PAREXEL International GmbH
001: Parexel Early Unit Berlin, Klinikum Westend Haus 31, Spandauer Damm 130, Berlin

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2024-11-20 2025-12-18 2024-11-20 2025-07-03

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-08-30 Germany Acceptable
2024-11-07
2024-11-12
2 NON SUBSTANTIAL MODIFICATION NSM-1 2025-07-08 Germany Acceptable
2024-11-07
2025-07-08